Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma

@article{Jimenez2013CurrentAF,
  title={Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma},
  author={C. Jimenez and E. Rohren and M. Habra and T. Rich and Paola Jim{\'e}nez and M. Ayala-Ramirez and E. Baudin},
  journal={Current Oncology Reports},
  year={2013},
  volume={15},
  pages={356-371}
}
  • C. Jimenez, E. Rohren, +4 authors E. Baudin
  • Published 2013
  • Medicine
  • Current Oncology Reports
  • Pheochromocytomas (PHs) and sympathetic paragangliomas (SPGs) are rare neuroendocrine tumors. Approximately 17 % of these tumors are malignant, but because no molecular or histologic markers for malignancy exist, patients are often diagnosed with malignant PHs or SPGs after unresectable disease has formed. Patients with progressive metastatic tumors and overwhelming symptoms are currently treated with systemic chemotherapy and radiopharmaceutical agents such as metaiodobenzylguanidine. These… CONTINUE READING
    110 Citations
    Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management
    • Oksana Hamidi
    • Medicine
    • Current opinion in endocrinology, diabetes, and obesity
    • 2019
    • 9
    Pheochromocytoma and Paraganglioma: From Treatment to Follow-up
    • Highly Influenced
    Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer
    • 23
    • PDF
    Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma
    • PDF
    Malignant pheochromocytoma–paraganglioma: pathogenesis, TNM staging, and current clinical trials
    • 43
    Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks
    • PDF

    References

    SHOWING 1-10 OF 105 REFERENCES
    Metastatic pheochromocytoma and paraganglioma: focus on therapeutics.
    • 84
    Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.
    • 20
    Clinical review: Current treatment of malignant pheochromocytoma.
    • 162
    • PDF
    Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
    • 135
    Management and Treatment of Pheochromocytomas and Paragangliomas
    • M. Mannelli
    • Medicine
    • Annals of the New York Academy of Sciences
    • 2006
    • 73
    • Highly Influential
    Treatment of malignant pheochromocytoma.
    • 89
    Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
    • 134
    • PDF
    The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
    • 253
    • PDF
    Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma.
    • L. Amar, M. Fassnacht, +4 authors P. Plouin
    • Medicine
    • Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
    • 2012
    • 57
    Changing paradigms in the treatment of malignant pheochromocytoma.
    • 47
    • PDF